Drug profile · INN
ianalumab
ianalumab is a tumor necrosis factor receptor superfamily member 13c binding agent.
NMPA: clinical trials
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — ianalumab
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.70
Quick answer
ianalumab is a tumor necrosis factor receptor superfamily member 13c binding agent.
Key facts
INN ianalumab
Mechanism Tumor necrosis factor receptor superfamily member 13C binding agent
Target Tumor necrosis factor receptor superfamily member 13C
Mechanism of action
Tumor necrosis factor receptor superfamily member 13C binding agent
Primary target: Tumor necrosis factor receptor superfamily member 13C
Approval history
| Authority | Status | Date |
|---|---|---|
| NMPA | clinical trials | — |
Pipeline programs
Frequently asked questions
What is ianalumab?
ianalumab is a tumor necrosis factor receptor superfamily member 13c binding agent.